Physical Component: Measured by SF-36, a 36-item patient questionnaire assessing health-related quality of life. In one study, people taking SOTYKTU saw an improvement in physical functioning at Week 16 vs those taking placebo (5.8 vs 3.8).
SF-36=36-item Short Form Survey.
SYMPTOM IMPROVEMENT
AT 4 MONTHS
In two clinical studies, of adults taking SOTYKTU
SAW NOTICEABLE IMPROVEMENT*
in relief from joint symptoms, tenderness, and swelling at 4 months compared to 34% and 39% for placebo.
SOTYKTU was studied in two large clinical trials:
- 1294 adults were studied
- 648 received SOTYKTU, and 646 received placebo (a pill with no medicine)
- Patients were assessed at 4 months and again at 1 year
SOTYKTU treats both adults with active psoriatic arthritis and moderate to severe plaque psoriasis.
*Based on an improvement score that combined multiple scores for: joint swelling and tenderness, pain, disability, inflammation, and both patient and doctor assessments.
WITH RELIEF YOU CAN FEEL, EVERYDAY ACTIVITIES COULD BE SO ON*
Improvement in physical function
*In a clinical trial, people taking SOTYKTU or placebo assessed their own abilities across the activities listed below on a scale from 0 to 3, with 0 being the best. At the start, the average score was 1.1 for people taking SOTYKTU vs 1.2 for placebo.
†As measured by the Health Assessment Questionnaire–Disability Index (HAQ-DI), a self-reported questionnaire that provides a physical function score from 0 to 3, with 0 being the best. Results were based on 8 sections that evaluate various aspects of daily life.
SOTYKTU in a Range of Symptoms
Symptoms were measured by ACR, made up of joint pain, tenderness, swelling, disability, inflammation, and both patient and doctor assessments. This study was designed to see the percent of people who had at least a 20% improvement in their overall symptoms. It wasn’t meant to measure changes in each individual symptom.
Joint Symptoms
Measured by ACR20, a reflection of symptom improvement. In one study, more people taking SOTYKTU achieved at least a 20% improvement in symptoms at Week 16 vs those taking placebo (54% vs 39%).
Tenderness
Measured by the number of tender joints. In one study, people on SOTYKTU saw an average decrease of 8 in their tender joint count vs 6 for placebo, starting the study with an average of 15 vs 17 (SOTYKTU vs placebo).
Pain
Measured by a 100-point scale called PtGA, people on SOTKYTU saw an average decrease of 21 in their pain scores compared with 14 on placebo, starting the study with an average score of 59 vs 60 (SOTYKTU vs placebo).
Swelling
Measured by the number of swollen joints. In one study, people on SOTYKTU saw an average decrease of 5 in their swollen joint count vs 4 for placebo, starting the study with an average of 9 vs 10 (SOTYKTU vs placebo).
Dactylitis
(swelling of the fingers or toes)
Measured by a scale called LDI. In a combined analysis of two studies, 58% of people taking SOTYKTU saw dactylitis resolution by achieving a score of 0 at Week 16 compared with 44% taking placebo.
The study could not clearly determine a significant difference between SOTYKTU and placebo.
Skin Plaques
Measured by PASI, a scale that reflects psoriasis plaque response. In one study, more people with skin plaques taking SOTYKTU for active psoriatic arthritis saw 75% clearer skin at Week 16 vs those taking placebo (41% vs 15%).
ACR=American College of Rheumatology; ACR20=American College of Rheumatology 20% improvement criteria; LDI=Leeds Dactylitis Index; PASl=Psoriasis Area and Severity Index; PASI 75=≥75% improvement from baseline PASI; PtGA=Patient’s Global Assessment.
Your results may vary.
RESULTS OVER TIME
SOTYKTU treats both joint and skin symptoms,* with relief that lasts.
Adults taking SOTYKTU noticed fewer joint symptoms including swelling and tenderness at 4 months and at 1 year.†
*In one study, more people taking SOTYKTU saw 75% clearer skin at Week 16 vs those taking placebo (41% vs 15%). At Week 52, 54% of people taking SOTYKTU saw 75% clearer skin.
†As measured by ACR20, indicating at least a 20% improvement in psoriatic arthritis symptoms at Week 16 and Week 52.
Your results may vary.
ACR20=American College of Rheumatology 20% improvement criteria.
